HROW HARROW, INC.
Company Analysis
Latest News
Harrow to Acquire Global Rights to TYRVAYA from Viatris for up to $100M
Harrow, Inc. has entered into a definitive agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a nasal spray for the treatment of dry eye...
Harrow Relaunches First Lucentis Biosimilar, Targeting $9 Billion US Market
Harrow has launched BYOOVIZ® (ranibizumab-nuna) in the United States. The product is the first FDA-approved biosimilar to Genentech’s Lucentis®. Samsung...
🟢 Harrow Health is trading 5.4% up today as it rebounds from recent weakness with no clear catalyst identified
Harrow Health is trading at $39.49 (5.4% up) in after-hours trading, rebounding from recent weakness observed over the past week. • No fresh company-specific...
🔴 Harrow Health is trading 6.7% down today amid a broader biotech risk-off tone
Harrow Health is trading at $39.08 (-6.70%) today amid a broader biotech risk-off tone, as no clear company-specific catalyst surfaced in the available news...
Harrow Unveils Positive IHEEZO and BYOOVIZ Data at ASRS 2026
Harrow presented three clinical and real-world studies for IHEEZO and BYOOVIZ at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. These...
🟢 Harrow Health is trading 5.3% up today as investors partially reverse a sharp earnings-related selloff
Harrow Health is trading 5.3% up today at $47.26 as investors step back in to partially reverse a sharp earnings-related plunge from the prior session. • The...
Harrow Health Plunges Again After Earnings Miss — Can a Loaded Second Half Rescue the Bull Case?
Shares of Harrow Health (HROW) tumbled 10.9% to $40.00 in after-hours trading on July 17, erasing a week of steady gains and underscoring how fragile investor...
🔴 Harrow Health is trading 10.9% down today after recent earnings-driven volatility
Harrow Health is trading at $40.00, down 10.9% in after-hours trading, marking a sharp reversal after several days of gains. • The decline follows a period of...
🟢 Harrow Health is trading 5% up today amid a broader healthcare sector rally
Harrow Health is trading 5% up at $45.09 amid a strong move in healthcare stocks, driven by sector-wide momentum and positive industry sentiment. • The Health...
Harrow launches BYOOVIZ in U.S., targeting $9 billion anti-VEGF market
Harrow launched the U.S. commercialization of BYOOVIZ (ranibizumab-nuna). This FDA-approved biosimilar is interchangeable with Genentech's LUCENTIS. The...
Harrow Faces Growth Scrutiny, as Grow Funds Exits After Earnings Miss
Grow Funds exited its position in Harrow, Inc. on June 25, 2026, following disappointing earnings. This development places the company's 2026 revenue guidance...
🟢 Harrow Health Inc is trading 5.2% up today after reaffirming 2026 revenue guidance
Harrow Health Inc is trading 5.2% up today at $40.40, extending a strong multi-day rebound from early June lows. • The move follows the company's recent...
🟢 Harrow Health Inc is trading 5.3% up today as VERKAZIA relaunch rally continues
Harrow Health Inc is trading at $39.65 (up 5.3%) as the U.S. relaunch of its VERKAZIA ophthalmic treatment continues to fuel a sharp multi-day advance. •...
🟢 Harrow Health Inc is trading 5.14% up today as VERKAZIA relaunch fuels extended rally
Harrow Health Inc is trading 5.14% up today at $39.59, extending a significant rally that began on June 10. • The primary catalyst for the move is the...
🟢 Harrow Health Inc is trading 5.0% up today as VERKAZIA relaunch fuels extended rally
Harrow Health Inc is trading 5.0% up now at $37.70, extending its sharp rally from June 10 after the re-launch of its prescriptive VKC eye treatment, VERKAZIA,...
🟢 Harrow Health Inc is trading 10.25% up today on VERKAZIA eye treatment re-launch
Harrow Health Inc is trading at $36.89 (+10.25%) after the re-launch of its prescriptive VKC eye treatment, VERKAZIA, sparked renewed investor optimism. • The...
🟢 Harrow Health Inc is trading 7% up today on VERKAZIA eye treatment re-launch
Harrow Health Inc is trading 7% up at $35.81 following the re-launch of its prescriptive VKC eye treatment, VERKAZIA, which has sparked renewed investor...
🟢 Harrow Health Inc is trading 6.6% higher after announcing the re-launch of its VKC treatment, VERKAZIA®
Harrow Health Inc is trading 6.6% higher at $35.65 after the company announced the re-launch of VERKAZIA®, a prescription therapy for the allergic eye disease...
🟢 Harrow Health Inc is trading 5.5% up as new investor presentation highlights growth outlook
Harrow Health Inc is trading at $35.15 (5.5% up) after the company provided a fresh business outlook to investors. • On June 3, the company released a new...